CARMAT announces the end of its investigations on previously identified quality issues – 12/23/2021 at 07:00


Stéphane Piat, CEO of CARMAT, comments: “After more than two weeks of in-depth investigations, I am delighted that our teams were able to identify the origin of the quality problem that arose, and to propose corrective actions. Given the importance of the unmet needs of patients with end-stage biventricular heart failure who cannot benefit from a heart transplant, and the high demand from many physicians and hospitals for Aeson®, we will work diligently with all regulatory stakeholders in order to resume implantations as soon as possible, while keeping quality and patient safety as our top priorities. “

To receive all of CARMAT’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.



Source link -86